TWI506026B - 純化之吡咯并喹啉基－吡咯啶－２，５－二酮組成物以及製造與使用彼之方法 - Google Patents

純化之吡咯并喹啉基－吡咯啶－２，５－二酮組成物以及製造與使用彼之方法 Download PDF

Info

Publication number
TWI506026B
TWI506026B TW099145242A TW99145242A TWI506026B TW I506026 B TWI506026 B TW I506026B TW 099145242 A TW099145242 A TW 099145242A TW 99145242 A TW99145242 A TW 99145242A TW I506026 B TWI506026 B TW I506026B
Authority
TW
Taiwan
Prior art keywords
cancer
dione
dihydro
pyrrolo
trans
Prior art date
Application number
TW099145242A
Other languages
English (en)
Chinese (zh)
Other versions
TW201141865A (en
Inventor
大衛 瑞德
尼爾 邦恩斯
約翰 坎恩
克里斯多佛 李
陳劍協
馬丁 瑞德蒙
Original Assignee
亞闊股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 亞闊股份有限公司 filed Critical 亞闊股份有限公司
Publication of TW201141865A publication Critical patent/TW201141865A/zh
Application granted granted Critical
Publication of TWI506026B publication Critical patent/TWI506026B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW099145242A 2009-12-23 2010-12-22 純化之吡咯并喹啉基－吡咯啶－２，５－二酮組成物以及製造與使用彼之方法 TWI506026B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23

Publications (2)

Publication Number Publication Date
TW201141865A TW201141865A (en) 2011-12-01
TWI506026B true TWI506026B (zh) 2015-11-01

Family

ID=44188284

Family Applications (3)

Application Number Title Priority Date Filing Date
TW105127477A TW201643163A (zh) 2009-12-23 2010-12-22 純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法
TW104125790A TWI557125B (zh) 2009-12-23 2010-12-22 純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法
TW099145242A TWI506026B (zh) 2009-12-23 2010-12-22 純化之吡咯并喹啉基－吡咯啶－２，５－二酮組成物以及製造與使用彼之方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TW105127477A TW201643163A (zh) 2009-12-23 2010-12-22 純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法
TW104125790A TWI557125B (zh) 2009-12-23 2010-12-22 純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法

Country Status (19)

Country Link
US (3) US8552192B2 (OSRAM)
EP (2) EP2515904A4 (OSRAM)
JP (2) JP2013515737A (OSRAM)
KR (2) KR101669707B1 (OSRAM)
CN (2) CN102834097B (OSRAM)
AU (2) AU2010336533B9 (OSRAM)
BR (1) BR112012015656A2 (OSRAM)
CA (1) CA2785503A1 (OSRAM)
CO (1) CO6561823A2 (OSRAM)
HK (1) HK1215025A1 (OSRAM)
MX (1) MX2012007259A (OSRAM)
MY (2) MY169232A (OSRAM)
NZ (2) NZ600800A (OSRAM)
PH (2) PH12012501293A1 (OSRAM)
RU (1) RU2556205C2 (OSRAM)
SG (1) SG181927A1 (OSRAM)
TW (3) TW201643163A (OSRAM)
WO (1) WO2011079142A2 (OSRAM)
ZA (1) ZA201204759B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2354267T3 (es) * 2005-02-09 2011-03-11 Arqule, Inc. Derivados de maleimida, composiciones farmacéuticas y métodos para el tratamiento del cáncer.
CA2785503A1 (en) * 2009-12-23 2011-06-30 Arqule, Inc. Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
US9180099B2 (en) * 2011-07-07 2015-11-10 Arqule Inc. Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
CA2870520A1 (en) * 2012-04-23 2013-10-31 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same
JP2016527227A (ja) * 2013-07-16 2016-09-08 ドクター レディズ ラボラトリーズ リミテッド ペメトレキセドトロメタミン塩の新規な結晶形
KR20240063198A (ko) 2017-08-11 2024-05-09 액투에이트 테라퓨틱스 인크. 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의고체 형태
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2024513502A (ja) * 2021-04-07 2024-03-25 ユリカ セラピューティクス インコーポレイテッド Ｕｒａｔ１阻害剤、医薬組成物及びその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060223760A1 (en) * 2005-02-09 2006-10-05 Li Chiang J Compositions and methods for treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
EP1242420A2 (en) * 1999-12-16 2002-09-25 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
ATE315017T1 (de) * 2002-07-31 2006-02-15 Firmenich & Cie Verfahren zur racematspaltung einer sclareolid- vorstufe
WO2006031770A1 (en) * 2004-09-10 2006-03-23 Wyeth Process for the scalable synthesis of 1, 3, 4, 9-tetrahydropyrano[3, 4-b]-indole derivatives
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
JP5425060B2 (ja) 2007-06-22 2014-02-26 アークル インコーポレイテッド ピロリジノン、ピロリジン−２，５−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
ATE522531T1 (de) * 2007-06-22 2011-09-15 Arqule Inc Indolylpyrrolidine zur behandlung von krebs
CA2785503A1 (en) * 2009-12-23 2011-06-30 Arqule, Inc. Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
CA2870520A1 (en) * 2012-04-23 2013-10-31 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060223760A1 (en) * 2005-02-09 2006-10-05 Li Chiang J Compositions and methods for treatment of cancer

Also Published As

Publication number Publication date
KR101669707B1 (ko) 2016-10-27
TW201141865A (en) 2011-12-01
CN102834097A (zh) 2012-12-19
US20110160242A1 (en) 2011-06-30
AU2010336533B9 (en) 2015-10-08
TWI557125B (zh) 2016-11-11
HK1215025A1 (zh) 2016-08-12
EP2515904A2 (en) 2012-10-31
MY169232A (en) 2019-03-19
US9499540B2 (en) 2016-11-22
EP3081567A2 (en) 2016-10-19
AU2015243015B2 (en) 2017-02-02
TW201542546A (zh) 2015-11-16
KR20160121602A (ko) 2016-10-19
MX2012007259A (es) 2015-05-15
CA2785503A1 (en) 2011-06-30
AU2010336533B2 (en) 2015-09-10
PH12014500310A1 (en) 2015-09-28
AU2015243015A1 (en) 2015-11-05
PH12012501293A1 (en) 2013-01-07
NZ600800A (en) 2014-10-31
CN102834097B (zh) 2015-06-17
CN104910159A (zh) 2015-09-16
JP2016041712A (ja) 2016-03-31
CO6561823A2 (es) 2012-11-15
SG181927A1 (en) 2012-07-30
NZ628087A (en) 2016-02-26
EP3081567A3 (en) 2016-11-16
US8871933B2 (en) 2014-10-28
BR112012015656A2 (pt) 2016-05-10
JP2013515737A (ja) 2013-05-09
US8552192B2 (en) 2013-10-08
MY156701A (en) 2016-03-15
ZA201204759B (en) 2014-03-26
US20140031551A1 (en) 2014-01-30
RU2012131344A (ru) 2014-01-27
RU2556205C2 (ru) 2015-07-10
KR20120113760A (ko) 2012-10-15
AU2010336533A1 (en) 2012-07-12
WO2011079142A3 (en) 2011-11-24
US20160024076A1 (en) 2016-01-28
TW201643163A (zh) 2016-12-16
WO2011079142A2 (en) 2011-06-30
EP2515904A4 (en) 2013-07-03

Similar Documents

Publication Publication Date Title
TWI506026B (zh) 純化之吡咯并喹啉基－吡咯啶－２，５－二酮組成物以及製造與使用彼之方法
KR101974673B1 (ko) 치환된 이미다조피리디닐-아미노피리딘 화합물
CN107074769B (zh) 用于治疗增生性病症的组合物和方法
JP2017190337A (ja) がんを処置するための組合せ治療
JP2019521980A (ja) Ｊａｋ阻害剤としてのピロロピリミジン化合物の結晶
EP4353724A1 (en) Compound as cdk kinase inhibitor and use thereof
WO2022111644A1 (zh) 含氮杂环类衍生物的盐、晶型及其制备方法和应用
TW201307347A (zh) 經取代苯並－咪唑並－吡啶並－二氮呯化合物
US8343977B2 (en) Substituted triazolo-pyrimidine compounds
CN104884456B (zh) PI3K和/或mTOR抑制剂
JP5984837B2 (ja) ピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにそれを調製および使用する方法
CN121005700A (zh) 一种用于制备atm激酶抑制剂的咪唑并[4,5-c]喹啉-2-酮衍生物